Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Iovance Biotherapeutics Shares Soared as Much as 39.6%

By Maxx Chatsko - Updated Feb 25, 2020 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bloomberg reports that the company has been toying with the idea of a sale.

What happened

Shares of Iovance Biotherapeutics (IOVA 7.54%) jumped nearly 40% today after Bloomberg reported that the company has held early discussions with potential buyers. The report also cautioned that the cellular therapy developer could bail out of discussions and remain an independent company. 

Many large companies have expressed interest in acquiring promising assets in genetic medicines, cellular therapies, and gene therapy manufacturing. Many already have made such acquisitions. Considering Iovance Biotherapeutics has solid data in hand for two drug candidates and is only valued at $4 billion with today's pop, the Bloomberg report isn't surprising. 

As of 3:24 p.m. EST on Tuesday, the pharma stock had settled to a 26.6% gain.

An arrow bouncing up shelves on a wall.

Image source: Getty Images.

So what

Iovance has demonstrated impressive results in mid-stage trials for two of its tumor infiltrating lymphocyte (TIL) therapies. 

In a phase 2 trial, the lead drug candidate lifileucel achieved an objective response rate of 36% in 66 individuals with advanced melanoma. Objective response rate measures the number of individuals who achieve tumor shrinkage after treatment. The median duration of response had not been reached at 11.3 months. Both metrics are impressive considering metastatic melanoma is one of the deadliest cancers.

And in a separate phase 2 study, an experimental asset named LN-145 achieved an overall response rate of 44.4% in 27 evaluable patients with cervical cancer. Treatments on the market today have achieved overall response rates of 4% to 14%. 

Both experimental assets are widely expected to earn marketing approval in the next year or two. 

Now what

The field of cellular immunotherapy holds tremendous promise and could lead to significantly improved outcomes for patients. Iovance Biotherapeutics is one of the few companies today with evidence that its approach works in real patients, which could make it an attractive takeover target. Investors shouldn't necessarily count on a sale or get too carried away with speculation, but the long-term potential of the company remains intact even if a deal falls through.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
IOVA
$11.13 (7.54%) $0.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.